PURPOSE To assess biologic features related to the development of immune thrombocytopenia (ITP) in patients with chronic lymphocytic leukemia (CLL). EXPERIMENTAL DESIGN We retrospectively analyzed 463 patients with CLL with available immunoglobulin heavy-chain variable (IGHV) gene status and B-cell receptor (BCR) configuration [heavy-chain complementary-determining region 3 (HCDR3)], of whom ...

Platelet production and circulation Thrombopoietin (TPO), the major cytokine affecting all phases of platelet production, is produced primarily by the liver and binds to the c-Mpl receptor located on platelets, stem cells and megakaryocytes. Upon stimulation, pluripotential stem cells produce cells committed to megakaryocyte differentiation. These cells initially undergo mitosis followed eventu...

Chronic idiopathic thrombocytopenic purpura (chronic ITP) is an autoimmune disorder characterized by bleeding tendency and the presence of auto-antibody to platelets. Quantitative analysis of the level of anti-platelet antibodies and platelet associated antibodies is now possible. Furthermore, recent immunological techniques have enabled us to detect target platelet antigens in chronic ITP. In ...

Objective: We aimed to investigate the incidence of hearing loss in patients followed up for Chronic Immune Thrombocytopenia Purpura (ITP). Material and Methods: All over age 18 who referred hematology outpatient clinic between January June 2020 with diagnosis ITP were included study. Hearing tests diagnosed received first-line treatment (IVIG corticosteroid) any reason other than ear diseases ...

BACKGROUND Chronic immune thrombocytopenia (ITP) is a condition associated with significant morbidity; however the management options are often unsatisfactory with a portion of patients exhibiting a refractory-relapsing disease path despite various lines of treatment including splenectomy. As a thrombopoietin receptor agonist, eltrombopag (GlaxoSmithKline, Australia) provides a novel treatment ...

Romiplostim is a thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura (ITP) who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Although thrombotic and embolic complications have been reported in patients receiving romiplostim, these have generally involved coronary artery or...

Immune thrombocytopenia (ITP), with an incidence of 3–5 per 100,000 individuals, is diagnosed by exclusion. Erythrovirus B19 (EV19) infection has been reported to be associated with ITP in from 13% to 50% of cases.1–3 Combined chronic red cell hypoplasia and thrombocytopenia has been rarely reported in otherwise healthy individuals. We report a case of EV19-induced erythroid hypoplasia and thro...

BACKGROUND AND OBJECTIVES The CD40-CD40L system has pleiotropic effects in a variety of cells and biological processes including the immune response. Within the immune system, these molecules represent a critical link between its humoral and cellular arms. Immune or idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by antibody-induced platelet destruction and cle...

Background: Immune thrombocytopenia purpura (ITP) is one of the most common autoimmune diseases in children characterized by a decreased number circulating platelets combined with impaired platelet production. There limited literature data on prevalence and treatment modalities, outcome ITP from Lebanon. Methods: We retrospectively reviewed demographic clinical 59 patients aged 0–18 years diagn...

Objective: This work aimed to report our observations on idiopathic or immune thrombocytopenic purpura (ITP) in elderly patients. Patients and Methods: We retrospectively reviewed a cohort of 41 consecutive elderly ITP patients (≥65 years old) in two ITP reference centers, namely the university hospital groups of Strasbourg and Reims, France. We particularly analyzed patient clinical characteri...